Steven Cohen’s BIO Holdings & Trades

First Buy
Q3 2015
Duration Held
41 Quarters
Largest Add
Q3 2024
+250,108 Shares
Current Position
10,195 Shares
$2.86 M Value

Steven Cohen's BIO Position Overview

Steven Cohen (via Point72 Asset Management, L.P.) currently holds 10,195 shares of Bio-Rad Laboratories, Inc. (BIO) worth $2.86 M, representing 0.00% of the portfolio. First purchased in 2015-Q3, this long-term strategic position has been held for 41 quarters.

Based on 13F filings since 2013, Steven Cohen has maintained a long-term strategic position in BIO, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2024, adding 178,708 shares. Largest reduction occurred in Q1 2025, reducing 212,906 shares.

Analysis based on 13F filings available since 2013 Q2

Steven Cohen's Bio-Rad Laboratories (BIO) Holding Value Over Time

Track share changes against reported price movement

Quarterly Bio-Rad Laboratories (BIO) Trades by Steven Cohen

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2015 +73,700 New Buy 73,700 $134.31
Q4 2015 -14,900 Reduce 20.22% 58,800 $138.66
Q1 2016 -58,800 Sold Out 58,800 $0.00
Q2 2016 +38,800 New Buy 38,800 $143.02
Q3 2016 -500 Reduce 1.29% 38,300 $163.81
Q4 2016 -25,600 Reduce 66.84% 12,700 $182.28
Q1 2017 +81,400 Add 640.94% 94,100 $199.34
Q2 2017 -94,100 Sold Out 94,100 $0.00
Q1 2018 +108,200 New Buy 108,200 $250.08
Q2 2018 -8,597 Reduce 7.95% 99,603 $288.54
Q3 2018 +30,943 Add 31.07% 130,546 $312.99
Q4 2018 -4,071 Reduce 3.12% 126,475 $232.22
Q1 2019 +10,901 Add 8.62% 137,376 $305.68
Q2 2019 +147,643 Add 107.47% 285,019 $312.59
Q3 2019 -146,736 Reduce 51.48% 138,283 $332.74
Q4 2019 -103,441 Reduce 74.80% 34,842 $370.04
Q1 2020 -34,842 Sold Out 34,842 $0.00
Q2 2020 +14,305 New Buy 14,305 $451.52
Q3 2020 -14,305 Sold Out 14,305 $0.00
Q4 2020 +6,300 New Buy 6,300 $583.02
Q1 2021 -6,300 Sold Out 6,300 $0.00
Q2 2021 +11,800 New Buy 11,800 $644.32
Q3 2021 +23,724 Add 201.05% 35,524 $745.95
Q4 2021 +43,534 Add 122.55% 79,058 $755.57
Q1 2022 +36,345 Add 45.97% 115,403 $563.23
Q2 2022 +26,279 Add 22.77% 141,682 $495.00
Q3 2022 -52,164 Reduce 36.82% 89,518 $417.15
Q4 2022 +34,908 Add 39.00% 124,426 $420.49
Q1 2023 +50,424 Add 40.53% 174,850 $479.02
Q2 2023 -101,391 Reduce 57.99% 73,459 $379.12
Q3 2023 -73,459 Sold Out 73,459 $0.00
Q1 2024 +71,400 New Buy 71,400 $345.87
Q2 2024 -71,400 Sold Out 71,400 $0.00
Q3 2024 +250,108 New Buy 250,108 $334.58
Q4 2024 -2,598 Reduce 1.04% 247,510 $328.51
Q1 2025 -212,906 Reduce 86.02% 34,604 $243.56
Q2 2025 -34,604 Sold Out 34,604 $0.00
Q3 2025 +10,195 New Buy 10,195 $280.39

Steven Cohen's Bio-Rad Laboratories Investment FAQs

Steven Cohen first purchased Bio-Rad Laboratories, Inc. (BIO) in Q3 2015, acquiring 73,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen has held Bio-Rad Laboratories, Inc. (BIO) for 41 quarters since Q3 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen's largest addition to Bio-Rad Laboratories, Inc. (BIO) was in Q3 2024, adding 250,108 shares worth $83.68 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 10,195 shares of Bio-Rad Laboratories, Inc. (BIO), valued at approximately $2.86 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, Bio-Rad Laboratories, Inc. (BIO) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen's peak holding in Bio-Rad Laboratories, Inc. (BIO) was 285,019 shares, as reported at the end of Q2 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.